Central Nervous System Diseases  >>  Zecuity (transdermal sumatriptan)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zecuity (transdermal sumatriptan) / Teva
NP101-007, NCT00724815: The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

Checkmark Treatment of acute migraine (IHC 2013)
Jun 2013 - Jun 2013: Treatment of acute migraine (IHC 2013)
Checkmark Migraine patients with or without nausea (IHC 2013)
Jun 2013 - Jun 2013: Migraine patients with or without nausea (IHC 2013)
Checkmark Pivotal P3 data
More
Completed
3
530
US
NP101 - Sumatriptan iontophoretic transdermal patch, Sumatriptan, Placebo, NP101 Placebo
NuPathe Inc.
Migraine Disorders
07/09
07/09
NP101-008, NCT00792103: An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

Completed
3
198
US
NP101
NuPathe Inc.
Migraine Disorders
09/10
09/10
NP101-009, NCT00806546: An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

Completed
3
514
US
NP101
NuPathe Inc.
Migraine Disorders
05/11
05/11

Download Options